Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;29(10):919-23.
doi: 10.1097/INF.0b013e3181e232ea.

Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines

Affiliations

Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines

Sung-Sil Moon et al. Pediatr Infect Dis J. 2010 Oct.

Abstract

Background: Live oral rotavirus vaccines have been less immunogenic and efficacious among children in poor developing countries compared with middle income and industrialized countries for reasons that are not yet completely understood. We assessed whether the neutralizing activity of breast milk could lower the titer of vaccine virus and explain this difference in vitro.

Methods: Breast milk samples were collected from mothers who were breast-feeding infants 4 to 29 weeks of age (ie, vaccine eligible age) in India (N = 40), Vietnam (N = 77), South Korea (N = 34), and the United States (N = 51). We examined breast milk for rotavirus-specific IgA and neutralizing activity against 3 rotavirus vaccine strains-RV1, RV5 G1, and 116E using enzyme immunoassays. The inhibitory effect of breast milk on RV1 was further examined by a plaque reduction assay.

Findings: Breast milk from Indian women had the highest IgA and neutralizing titers against all 3 vaccine strains, while lower but comparable median IgA and neutralizing titers were detected in breast milk from Korean and Vietnamese women, and the lowest titers were seen in American women. Neutralizing activity was greatest against the 2 vaccine strains of human origin, RV1 and 116E. This neutralizing activity in one half of the breast milk specimens from Indian women could reduce the effective titer of RV1 by ∼2 logs, of 116E by 1.5 logs, and RV5 G1 strain by ∼1 log more than that of breast milk from American women.

Interpretation: The lower immunogenicity and efficacy of rotavirus vaccines in poor developing countries could be explained, in part, by higher titers of IgA and neutralizing activity in breast milk consumed by their infants at the time of immunization that could effectively reduce the potency of the vaccine. Strategies to overcome this negative effect, such as delaying breast-feeding at the time of immunization, should be evaluated.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Cumulative frequency profiles of rotavirus-specific antibodies in breast milk specimens from mothers in India, Vietnam, Korea and the United States. Milk specimens were tested for IgA (A) and neutralizing activity against vaccine strains Rotarix (B), RotaTeq G1 (C), and 116E (D) as described in the text. Nearly all Indian women had an IgA titier >16 versus all other women. The median IgA and neutralizing titers and the distribution of titers for breast milk from Indian women were higher than all others. The values of significance between Indian women and those from Korea, Vietnam, and the United States are indicated. NA indicates neutralizing antibody.
FIGURE 2
FIGURE 2
Reduction in titer of Rotarix by breast milk from India and United States. Selected breast milk specimens with low and high neutralizing titer from the United States (A, B) and India (C, D) were tested for reduction in viral titer as described in the text. While breast milk with low titers demonstrated only modest neutralization activity that was quenched with dilution, breast milk with higher titer, particularly those from India, could be diluted 1:128–1:512 and still neutralize the vaccine virus. NT indicates neutralizing titer.

Similar articles

Cited by

References

    1. Parashar UD, Gibson CJ, Bresse JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12:304–306. - PMC - PubMed
    1. World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec. 2007;82:285–295. - PubMed
    1. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. - PubMed
    1. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33. - PubMed
    1. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J. 2004;23:937–943. - PubMed

Publication types

MeSH terms